These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30037640)

  • 41. Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.
    Klos D; Riško J; Stašek M; Loveček M; Hanuliak J; Skalický P; Lemstrová R; Mohelníková BD; Študentová H; Neoral Č; Melichar B
    Cas Lek Cesk; 2018 Dec; 157(8):419-428. PubMed ID: 30754979
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis.
    Rihuete Caro C; Manzanedo I; Pereira F; Carrion-Alvarez L; Serrano Á; Pérez-Viejo E
    Eur J Surg Oncol; 2018 Nov; 44(11):1805-1810. PubMed ID: 30087071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A critical look at local-regional management of peritoneal metastasis.
    Chan CH; Cusack JC; Ryan DP
    Hematol Oncol Clin North Am; 2015 Feb; 29(1):153-8. PubMed ID: 25475577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postoperative complications affect long-term outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.
    Lee L; Alie-Cusson F; Dubé P; Sideris L
    J Surg Oncol; 2017 Aug; 116(2):236-243. PubMed ID: 28409831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment for peritoneal metastasis of colorectal cancer].
    Wang L; Cai J; Qin QY
    Zhonghua Wai Ke Za Zhi; 2018 Aug; 56(8):569-572. PubMed ID: 30107696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytoreductive surgery and HIPEC in treatment of colorectal peritoneal carcinomatosis: experiment or standard care? A survey among oncologic surgeons and medical oncologists.
    Braam HJ; Boerma D; Wiezer MJ; van Ramshorst B
    Int J Clin Oncol; 2015 Oct; 20(5):928-34. PubMed ID: 25788217
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prolonged perioperative thoracic epidural analgesia may improve survival after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A comparative study.
    Lorimier G; Seegers V; Coudert M; Dupoiron D; Thibaudeau E; Pouplin L; Lebrec N; Dubois PY; Dumont F; Guérin-Meyer V; Capitain O; Campone M; Wernert R
    Eur J Surg Oncol; 2018 Nov; 44(11):1824-1831. PubMed ID: 30213715
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
    van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
    Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Pseudomyxoma Peritonei.
    Kusamura S; Delhorme JB; Taibi A; Villeneuve L; Deraco M; Dico RL; Glehen O; Moran B
    Ann Surg Oncol; 2024 Sep; 31(9):6262-6273. PubMed ID: 39008204
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Curr Oncol; 2020 Jun; 27(3):146-154. PubMed ID: 32669924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
    Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
    Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
    Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O;
    Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI).
    Goéré D; Passot G; Gelli M; Levine EA; Bartlett DL; Sugarbaker PH; Glehen O
    Int J Hyperthermia; 2017 Aug; 33(5):520-527. PubMed ID: 28540827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups.
    Amblard I; Mercier F; Bartlett DL; Ahrendt SA; Lee KW; Zeh HJ; Levine EA; Baratti D; Deraco M; Piso P; Morris DL; Rau B; Tentes AAK; Tuech JJ; Quenet F; Akaishi E; Pocard M; Yonemura Y; Lorimier G; Delroeux D; Villeneuve L; Glehen O; Passot G;
    Eur J Surg Oncol; 2018 Sep; 44(9):1378-1383. PubMed ID: 30131104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peritoneal Carcinomatosis of Gastric Origin - Treatment Possibilities.
    Hoskovec D; Krška Z; Dytrych P; Vočka M
    Klin Onkol; 2019; 32(5):345-348. PubMed ID: 31610666
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis: a clinical pharmacological perspective on a surgical procedure.
    de Jong LAW; Elekonawo FMK; de Reuver PR; Bremers AJA; de Wilt JHW; Jansman FGA; Ter Heine R; van Erp NP
    Br J Clin Pharmacol; 2019 Jan; 85(1):47-58. PubMed ID: 30255585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatocellular Carcinoma Peritoneal Metastasis: Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Spiliotis J; Nikolaou G; Kopanakis N; Vassiliadou D; Terra A; Efstathiou E
    Gulf J Oncolog; 2017 May; 1(24):20-23. PubMed ID: 28797997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.